bluebird bio (NASDAQ:BLUE) Now Covered by StockNews.com

Research analysts at StockNews.com initiated coverage on shares of bluebird bio (NASDAQ:BLUE) in a research report issued to clients and investors on Saturday. The firm set a “sell” rating on the biotechnology company’s stock.

Several other brokerages have also recently issued reports on BLUE. Barclays reduced their price target on shares of bluebird bio from $40.00 to $8.00 and set an “overweight” rating on the stock in a research report on Monday, March 31st. JPMorgan Chase & Co. upgraded bluebird bio from an “underweight” rating to a “neutral” rating in a report on Monday, February 24th. Baird R W cut bluebird bio from a “strong-buy” rating to a “hold” rating in a research note on Friday, February 21st. Finally, Wells Fargo & Company dropped their price target on bluebird bio from $40.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Monday, February 24th. One investment analyst has rated the stock with a sell rating, six have assigned a hold rating and two have given a buy rating to the stock. According to MarketBeat.com, bluebird bio has a consensus rating of “Hold” and a consensus price target of $44.60.

bluebird bio Stock Performance

NASDAQ:BLUE opened at $4.95 on Friday. The company has a quick ratio of 0.33, a current ratio of 0.51 and a debt-to-equity ratio of 0.37. The firm’s fifty day simple moving average is $5.23 and its 200 day simple moving average is $7.51. The stock has a market cap of $48.46 million, a P/E ratio of -0.13 and a beta of 0.41. bluebird bio has a twelve month low of $3.56 and a twelve month high of $28.60.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Regeneron Pharmaceuticals Inc. bought a new stake in bluebird bio in the fourth quarter worth $175,000. Verition Fund Management LLC purchased a new position in shares of bluebird bio in the 3rd quarter worth about $42,000. Captrust Financial Advisors boosted its stake in bluebird bio by 48.2% in the 3rd quarter. Captrust Financial Advisors now owns 237,648 shares of the biotechnology company’s stock worth $123,000 after purchasing an additional 77,293 shares in the last quarter. Barclays PLC grew its position in bluebird bio by 273.7% during the 3rd quarter. Barclays PLC now owns 252,062 shares of the biotechnology company’s stock valued at $130,000 after purchasing an additional 184,605 shares during the last quarter. Finally, BNP Paribas Financial Markets grew its position in bluebird bio by 2,270.2% during the 3rd quarter. BNP Paribas Financial Markets now owns 371,224 shares of the biotechnology company’s stock valued at $193,000 after purchasing an additional 355,562 shares during the last quarter. Institutional investors own 87.43% of the company’s stock.

bluebird bio Company Profile

bluebird bio, Inc, a biotechnology company, researches, develops, and commercializes gene therapies for severe genetic diseases. Its product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; lovotibeglogene autotemcel for the treatment of sickle cell disease (SCD); and SKYSONA (elivaldogene autotemcel) to treat cerebral adrenoleukodystrophy.